DeepMed Research

Palmidrol

Generic Name: Palmidrol

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₃₇NO_₂

CAS Number: 544-31-0

Unique Ingredient Identifier: 6R8T1UDM3V

Background: A cannabinoid receptor-inactive eCB-related molecule used as prophylactic in helping to prevent respiratory viral infection. Palmidrol is available for human use as a supplement (400 mg capsules) and as food for medical purposes In Italy and Spain (300 mg and 600 mg tablets).

Clinical Trials

Palmitoylethanolamide for Chronic Inflammatory Pain Conditions

Phase 2

Recruiting

Conditions: Chronic Pain

Interventions: Drug: Palmitoylethanolamide 600mg twice a day
Other: placebo

First Posted Date: 2024-02-22

Last Posted Date: 2024-08-15

Lead Sponsor: Navy Medical Center San Diego

Target Recruit Count: 80

Registration Number: NCT06273462

Locations: 🇺🇸
Naval Medical Center San Diego, San Diego, California, United States

A Trial of the Fatty Acid Amide Hydrolase Inhibitor Palmitoylethanolamide in Bipolar Depression

Phase 2

Recruiting

Conditions: Bipolar Depression

Interventions: Drug: Palmitoylethanolamide (PEA)
Drug: Placebo
Drug: Treatment as Usual (TAU)

First Posted Date: 2024-01-29

Last Posted Date: 2024-01-29

Lead Sponsor: The University of Texas Health Science Center, Houston

Target Recruit Count: 50

Registration Number: NCT06229977

Locations: 🇺🇸
The University of Texas Health Science Center at Houston, Houston, Texas, United States

PEA vs. Placebo for Major Depression

Phase 2

Recruiting

Conditions: Major Depressive Disorder
Bipolar Depression

Interventions: Drug: Palmitoylethanolamide

First Posted Date: 2023-10-02

Last Posted Date: 2023-10-02

Lead Sponsor: The Israeli Medical Center for Alzheimer's

Target Recruit Count: 100

Registration Number: NCT06063369

Locations: 🇲🇩
State University of Medicine and Pharmacy " Nicolae Testemitsanu", Chișinău, Moldova, Republic of

Endocannabinoids, Stress, Craving And Pain Effects Study

Early Phase 1

Recruiting

Conditions: Opioid Use Disorder

Interventions: Other: Placebo
Drug: Palmitoylethanolamide

First Posted Date: 2022-07-29

Last Posted Date: 2024-02-26

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 16

Registration Number: NCT05480072

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Effect of Palmitoylethanolamide on Reducing Opioid Consumption for Below Knee Fracture Fixation

Phase 2

Withdrawn

Conditions: Tibial Fractures
Fibula Fracture
Knee Fracture

Interventions: Drug: Palmitoylethanolamide
Drug: Placebo

First Posted Date: 2022-04-08

Last Posted Date: 2023-05-09

Lead Sponsor: University of California, Irvine

Registration Number: NCT05317676

Locations: 🇺🇸
UC Irvine Medical Center, Orange, California, United States

PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy

Phase 2

Active, not recruiting

Conditions: Chemotherapy-Induced Peripheral Neuropathy
Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm

Interventions: Drug: Placebo Administration
Drug: Palmidrol
Other: Quality-of-Life Assessment

First Posted Date: 2022-02-18

Last Posted Date: 2025-01-24

Lead Sponsor: Academic and Community Cancer Research United

Target Recruit Count: 88

Registration Number: NCT05246670

Locations: 🇺🇸
Mayo Clinic Health System-Franciscan Healthcare, La Crosse, Wisconsin, United States
🇺🇸
Siouxland Regional Cancer Center, Sioux City, Iowa, United States
🇺🇸
Cone Health Cancer Center, Greensboro, North Carolina, United States

and more 7 locations

A Study Evaluating the Effectiveness of PEA Compared to Placebo for Reducing Pain Severity and Duration of Migraines.

Phase 3

Completed

Conditions: Migraine

Interventions: Drug: Palmitoylethanolamide sold as Levagen +
Drug: Placebo comparator - maltodextrin and microcrystalline cellulose mix

First Posted Date: 2021-09-16

Last Posted Date: 2023-10-24

Lead Sponsor: RDC Clinical Pty Ltd

Target Recruit Count: 80

Registration Number: NCT05046522

Locations: 🇦🇺
RDC Global Pty Ltd, Brisbane, Queensland, Australia

The Effectiveness of a Topical Palmitoylethanolamide (PEA) Formulation (Levagen+) for Reducing Symptoms of Eczema

Phase 2

Completed

Conditions: Eczema, Atopic

Interventions: Drug: 1.5% Palmitoylethanolamide (PEA) sold as Levagen+
Drug: Placebo Comparator

First Posted Date: 2021-08-12

Last Posted Date: 2023-11-18

Lead Sponsor: RDC Clinical Pty Ltd

Target Recruit Count: 72

Registration Number: NCT05003453

Locations: 🇦🇺
RDC Global Pty Ltd, Brisbane, Queensland, Australia

Efficacy of Ultra-micronized Palmitoylethanolamide (Um-PEA) in Geriatric Patients With Chronic Pain

Phase 4

Completed

Conditions: Chronic Pain

Interventions: Drug: ultra-micronized palmitoylethanolamide
Drug: Placebo

First Posted Date: 2016-03-04

Last Posted Date: 2019-09-11

Lead Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Target Recruit Count: 11

Registration Number: NCT02699281

Locations: 🇮🇹
Geriatric Unit, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milano, Italy

Acetylcholine Receptors From Human Muscles as Pharmacological Target for ALS

Not Applicable

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Riluzole
Drug: endocannabinoid palmitoylethanolamide (PEA)

First Posted Date: 2016-01-01

Last Posted Date: 2016-01-05

Lead Sponsor: University of Roma La Sapienza

Target Recruit Count: 50

Registration Number: NCT02645461

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy